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Taenia multiceps is a cestode parasite, the larval stage of which encysts in the brain of sheep, goats and cattle causing an often fatal
condition. The parasite also causes zoonotic infections in humans. Homologues of the recombinant oncosphere vaccine antigens from
Taenia ovis and other Taenia species were identiﬁed in T. multiceps. Sequencing of the associated T. multiceps genes and cloning of the
encoding mRNA has revealed conserved features in the genes and proteins. The T. multiceps oncosphere proteins, designated Tm16 and
Tm18, contain a predicted secretory signal and ﬁbronectin type III domain. The recombinant Tm16 and Tm18 proteins were successfully
expressed in Escherichia coli as fusion proteins with GST. The antigens, formulated with Quil A adjuvant, were tested in a vaccine trial in
sheep. The antigens stimulated immunity in sheep against challenge infection with T. multiceps eggs. Five of nine control sheep died due
to a challenge infection with T. multiceps whereas none of 20 vaccinated animals died as a result of the parasite challenge (P = 0.001). In
addition, vaccination with the Tm16 protein, or Tm16 plus Tm18, induced signiﬁcant protection against the number of parasites ency-
sting in the brain as a result of the challenge infection (P = 0.023, P = 0.015, respectively). No clear relationship was apparent between
the level of speciﬁc serum antibody in vaccinated animals and either the presence or absence of parasites or the number of parasites that
occurred in some of the vaccinated animals. We believe this study is the ﬁrst description of recombinant vaccine-related investigations for
T. multiceps. The recombinant oncosphere antigens identiﬁed may allow development of eﬀective vaccination strategies against T. mul-
ticeps infection in sheep. They raise the potential for the development of a combined vaccine with the Echinococcus granulosus EG95
antigen for prevention of T. multiceps as well as preventing the transmission of cystic hydatid disease.
 2007 Australian Society for Parasitology Inc. Published by Elsevier Ltd.
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Taenia multiceps is a cestode parasite, the larval stage of
which encysts in the CNS, mainly in the brain. The coenu-
rus larva grows to the size of a hen’s egg and causes neuro-0020-7519 2007 Australian Society for Parasitology Inc. Published by Elsev
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E-mail address: charlesg@unimelb.edu.au (C. Gauci).logical symptoms known as gid in infected sheep and goats
(Edwards and Herbert, 1982). The infection is commonly
lethal and the parasite is a signiﬁcant cause of economic
loss in many parts of the world involved in sheep/goat
grazing. The parasite also causes zoonotic infections in
humans (Pau et al., 1990; Sabattani et al., 2004), although
the condition is believed to be relatively rare.
The deﬁnitive hosts of T. multiceps are dogs and other
canids. Sheep become infected by ingestion of parasite eggs
passed in the faeces of the deﬁnitive host. The oncosphere
larval stage is liberated in the small intestine, penetrates theier Ltd. Open access under CC BY license. 
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where it encysts and develops over a number of months
into a mature, infective coenurus. The lifecycle is com-
pleted after scoleces contained within the coenurus are
ingested by the deﬁnitive host.
The global distribution of T. multiceps coincides in
many instances with the distribution of hydatid disease
caused by Echinococcus granulosus (Scala and Varcasia,
2006; Sharma and Chauhan, 2006). A highly eﬀective vac-
cine has been developed which can reduce hydatid infection
in livestock animals (Lightowlers et al., 1996a) and it is
believed that widespread use of the vaccine could reduce
the transmission of hydatid infection to humans. However,
there is little direct economic incentive for livestock owners
to utilise the vaccine. Development of a combined gid/
hydatid vaccine is one potential strategy which could
improve application of the hydatid vaccine by providing
an indirect economic incentive to livestock owners to vac-
cinate against hydatids. In addition, an eﬀective vaccine
against T. multiceps would be economically valuable in
its own right.
Recombinant antigen vaccines have been developed
against infection with a number of Taenia species including
Taenia ovis in sheep (Johnson et al., 1989; Harrison et al.,
1996), Taenia saginata in cattle (Lightowlers et al., 1996b)
and Taenia solium in pigs (Flisser et al., 2004; Gonzalez
et al., 2005). These vaccines utilise one or more of three
groups of oncosphere proteins that are known as the 16k,
18k and 45W groups, after their original description in T.
ovis. As an initial step towards the development of a com-
bined gid/hydatid vaccine, we have investigated the pres-
ence of genes related to the 16k and 18k antigen families
in the genome of T. multiceps, cloned and expressed the
genes and undertaken a vaccine trial in sheep with the
recombinant proteins against a challenge infection with
T. multiceps.
2. Materials and methods
2.1. Parasites and parasite infections
Taenia multiceps coenuri were obtained from the brains
of naturally infected sheep from the region of Nigde, Tur-
key. Three, 3 month old dogs of mixed breed were treated
with 0.1 ml/kg praziquantel (Droncit, Bayer) to ensure the
absence of any cestode infection. Five days later the dogs
were infected orally with 40 or 20 T. multiceps scoleces.
Approximately 8 weeks after infection the dogs were found
to have Taenia eggs in the faeces. Taenia multiceps tape-
worms were collected after humane euthanasia using an
overdose of suxamethonium chloride. The worms were
washed in water and the gravid segments collected and
stored at 4 C in antibiotic water (100 IU penicillin,
0.1 mg/ml streptomycin, 0.25 mg/ml amphotericin B;
Sigma) and used for DNA/RNA extraction. Subsequently,
a second T. multiceps infection was undertaken in two dogs
and mature eggs were obtained from fresh gravid tape-worm segments obtained from the dogs’ faeces. Eggs were
released from the segments using scissors and counted
using a Neubauer counting chamber prior to challenge
infection of sheep. All animal experiments received ethics
approval from the Animal Ethics Committee of the Veteri-
ner Kontrol ve Arastirma Enstitusu, Pendik, Istanbul,
Turkey.
A specimen of T. multiceps genomic DNA was also
obtained from a coenurus isolated from a naturally
infected sheep from Wales, UK.
2.2. Isolation of parasite nucleic acids
Tapeworm specimens were obtained and genomic DNA
was extracted as described previously (McManus et al.,
1985; Waterkeyn et al., 1995). Total cellular RNA was
extracted from T. multiceps eggs according to Puissant
and Houdebine (1990) using TRIZOL (Invitrogen).
2.3. PCR ampliﬁcation and cloning of tm16 and tm18 genes
PCR was used to amplify the tm18 gene from T. multi-
ceps genomic DNA (Welsh parasite sample) using Pfx
DNA polymerase (Invitrogen) as detailed in Gauci et al.
(2006) using the following primers: 5 0-GACGTTCACGAC
GACGAAGATG-3 0; 5 0-CATTACTAACACCCTGTATT
TGTAATCG-3 0. Duplicate PCR products were separated
by agarose gel electrophoresis, puriﬁed using a QIAquick
Gel Extraction Kit (Qiagen), A-tailed using Taq DNA
polymerase (Promega) according to the manufacturer’s
instructions and cloned into a pGEM-T Easy vector (Pro-
mega). The tm16 gene was ampliﬁed and cloned, as above,
using the following PCR primers: 5 0-CCGGAATTCATGC
TGCTTCAAGTTTGCCTC-3 0; 5 0-CCGCTCGAGGCCA
ACTGAGACAACACCTG-3 0. Primers were designed to
amplify the full gene sequence (2594 bp for tm16 and
1395 bp for tm18).
2.4. RT-PCR ampliﬁcation of tm16 and tm18 mRNA
Total RNA from T. multiceps eggs (Turkish parasite
sample) was reverse transcribed using Superscript II
Reverse Transcriptase (Invitrogen) using oligo(dT) priming
as detailed in Gauci et al. (2006). The egg cDNA was used
as a template for PCR ampliﬁcation using Pfx DNA poly-
merase (Invitrogen). For ampliﬁcation of the tm16 cDNA,
the following primers were used: 5 0-CCGGAATTCGAGG
GATACGTTGAATTTGGCG-30; 50-CCGCTCGAGGCC
AACTGAGACAACACCTG-30. The following primers were
used for ampliﬁcation of the tm18 cDNA: 50-CCGGAA
TTCGGTGGCCAAGATTCCAACAAACG-30; 50-CCGCT
CGAGCATTACTAACACCCTGTATTTGTAATCG-30.
2.5. Cloning into the pGEM-T vector
Duplicate PCR-ampliﬁed products were separated by
electrophoresis through Tris–Acetate–EDTA (TAE) aga-
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Gel Extraction Kit (Qiagen). Separate product bands were
cloned into the plasmid vector pGEM-T using the pGEM-
T Vector System I cloning kit (Promega). Escherichia coli
JM109 was used as the host cell line for the recombinant
plasmids.
2.6. DNA sequence analysis
The Wizard Plus DNA Puriﬁcation kit (Promega) was
used to prepare recombinant plasmids for use as template
in sequencing reactions. Sequencing was performed using
the Applied Biosystems PRISM automated sequencing
system with the ABI BigDye Terminator sequencing
kit. DNA and protein sequence was compiled using Accel-
rys DS Gene 2.5. PCR ampliﬁcation reactions were per-
formed in duplicate and products were cloned/sequenced
separately to ensure sequence accuracy.
2.7. Bacterial expression and preparation of recombinant
antigens for vaccination
The tm16 and tm18 cDNAs were excised from pGEM-T
by double digestion with EcoRI and XhoI, separated from
the plasmid by agarose gel electrophoresis and puriﬁed
from the gel using a QIAquick Gel Extraction Kit (Qia-
gen). The recovered cDNA inserts were ligated to EcoRI
and XhoI digested pGEX-1TEX (GE Healthcare Biosci-
ences) and transformed into E. coli by electroporation.
The primers used to amplify tm16 and tm18 from egg
mRNA, for subsequent E. coli expression, were designed
to produce recombinant proteins that were truncated by
removal of the predicted secretory signal sequence of each
antigen. This resulted in deletion of the 16 N-terminal
amino acids of Tm16 and 18 N-terminal amino acids of
Tm18. Escherichia coli BL21 DE3 was used for expression
of the recombinant antigens as fusion proteins with GST
(Smith and Johnson, 1988). Super optimal broth (SOB)
and 100 lg/ml ampicillin were inoculated with a bacterial
colony from an SOB agar culture and incubated in a shaker
incubator (Infors, Switzerland) at 37 C, 210 rpm for 16 h.
The overnight culture was diluted 1:10 in SOB containing
ampicillin and incubated further with shaking until the
O.D.595nm reached approximately 0.5–1 U. Recombinant
protein expression was induced by addition of isopropyl
b-D-thiogalactopyranoside (IPTG) at a concentration of
0.2 mM with incubation for a further 5 h. Bacteria were
recovered from the culture medium by centrifugation at
5000g and lysed by sonication using a Vibra Cell
VCX750 Sonicator (Sonics, CT, USA) ﬁtted with a
19 mm probe. The lysates were clariﬁed by centrifugation
at 40,000g at 4 C for 15 min. The GST fusion proteins
were puriﬁed by batch aﬃnity chromatography according
to Smith and Johnson (1988). The purity of the GST
fusions was determined by SDS–PAGE and scanning den-
sitometry (Molecular Dynamics). Protein concentration
was estimated using the method of Bradford (1976). Thepuriﬁed GST fusion proteins were mixed with Quil A
(Superfos, Denmark) and sixfold w/w maltose followed
by lyophilisation for transport and storage. The Tm16
and Tm18 antigens were reconstituted in sterile distilled
water prior to immunisation of lambs.
2.8. Bacterial expression and preparation of recombinant
antigens for ELISA
The tm16 and tm18 cDNAs were excised from pGEX-
1TEX by double digestion with EcoRI and XhoI, and
cloned into EcoRI/SalI digested pMAL-C2 (New England
Biolabs). The E. coli JM109 strain was used for expression
of the recombinant antigens as fusion proteins with malt-
ose-binding protein (MBP). Culturing and recovery of
MBP fusion proteins was performed as described in Sec-
tion 2.7 and Maina et al. (1988), except aﬃnity puriﬁcation
was performed using amylose resin (New England Biolabs)
and fusion proteins were eluted by the addition of 10 mM
maltose.
2.9. Vaccination trial with recombinant antigens
Thirty sheep, Akkaraman breed, aged 3–4 months were
divided into ﬁve groups. Three groups of seven sheep each
were immunised on three occasions, 2 weeks apart, with
aﬃnity puriﬁed fusion protein. One group was immunised
with 50 lg Tm16, one group with 50 lg Tm18 and one
group with 50 lg of each Tm16 and Tm18. One group of
ﬁve sheep was immunised with 50 lg GST and the remain-
ing four sheep received no immunisations. All immunisa-
tions were given by s.c. injection in the neck in a volume
of 2 ml together with 1 mg Quil A adjuvant (Superfos,
Denmark). Two weeks after the third injection, all sheep
were each infected with 5500 T. multiceps eggs by intra-
rumen injection through a 10 cm, 16 gauge needle. Four
months after infection, the sheep were humanely slaugh-
tered and the brain examined for T. multiceps coenuri.
The number and size of cysts, as well as their location, were
recorded using the scheme previously described by
Edwards and Herbert (1982). During the experiment blood
samples were obtained at 2 week intervals via the jugular
vein.
2.10. ELISA
Lambs vaccinated with Tm16, Tm18 or both proteins
(as GST fusion proteins) were assessed for speciﬁc anti-
body against the respective immunising antigens. The
recombinant proteins, fused to MBP, were bound to 96-
well microtitre plates (Greiner Bio-One) by incubating
0.25 lg per well in 50 ll carbonate buﬀer (10 mM Na2CO3,
30 mM NaHCO3, pH 9.6) for 16 h at 4 C. The plates were
blocked (1 h at 37 C) with 100 ll PBS (pH 7.2) containing
1% w/v sodium caseinate. After six washes with PBS con-
taining 0.05% Tween 20 (PBST), 50 ll of serial dilutions
of sheep serum samples were added to the wells for 1 h at
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PBST. After incubation, the plates were again washed six
times in PBST, and 50 ll per well of diluted donkey anti-
ovine IgG-horseradish peroxidase (HRP) conjugate (1/
5000 for Tm16 and 1/4000 for Tm18, Bethyl Laboratories
Inc.) was added in sodium caseinate-PBST, and the plates
incubated for a further 1 h at 37 C. The plates were
washed six times with PBST and TMB substrate (45 mM
dibasic sodium phosphate, 0.22 mM citric acid, 0.42 mM
3,3 0,5,5 0-tetramethylbenzidine and 2 · 102% H2O2) was
added (100 ll/well). The reaction was stopped after
30 min by the addition of 2 M H2SO4 (50 ll/well). The
O.D. was measured at 450 nm (Dynex Technologies Ltd.,
UK). Antibody titres were calculated for serum samples
as the dilution of sera that approximately equaled an
O.D. of 1.0 and are expressed as the reciprocal of that dilu-
tion. Positive and negative control sera were tested on each
plate and any plates on which the titre deviated from the
mean positive control titre by more than 20% were re-
assayed (Rothel et al., 1996).
IgG1 and IgG2 antibody isotypes were measured by the
addition of 50 ll per well of a pre-determined concentra-
tion of anti-isotype monoclonal antibody (Rothel et al.,
1996; Woollard et al., 1998) for 1 h at 37 C. Plates were
washed and 50 ll per well of a 1/1000 dilution of sheep
anti-mouse IgG-HRP (Sigma) was added for a 1 h incuba-
tion at 37 C. Plates were washed and developed as
described above.
2.11. Statistical methods
The Mann–Whitney U test was used for comparison of
the number of parasite coenuri or antibody titres found in
animals in diﬀerent groups. Fisher’s exact test was used for
comparing the proportion of animals which died following
the parasite infection. Spearman’s rank correlation coeﬃ-
cient determined the association between the antibody titre
and the number of cysts in vaccinated animals. The propor-
tion of cysts in the parieto-occipital location was compared
between the vaccinated and control animals using an exact
test for correlated binary data (Corcoran et al., 2001), as
implemented in StatXact 8.0 (Cytel Inc., Cambridge,
MA). Antibody titres are presented as mean ± SD A
two-tailed P value <0.05 was considered to be statistically
signiﬁcant.tm18
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3.1. Gene cloning and structure analysis
PCR ampliﬁcation from T. multiceps genomic DNA
using primers based on the 16k and 18k genes of T. ovis
and T. solium (Harrison et al., 1996; Gauci et al., 1998;
Gauci and Lightowlers, 2003) revealed products which sug-
gested that homologues of these genes occurred in T. mul-
ticeps. A 2594 bp gene product (tm16) and a 1395 bp
product (tm18) were ampliﬁed, cloned and the DNA
sequence of each was determined (GenBank Accession
Nos. EF672037 and EF672035, respectively). DNA
sequencing revealed that both the tm16 and tm18 genes
from T. multiceps consist of two exons separated by three
introns (Fig. 1). The positions of the protein-encoding
regions were conﬁrmed for each gene by ampliﬁcation
and cloning of tm16 and tm18 transcripts from T. multiceps
egg mRNA. The cDNA sequence of tm16 and tm18 con-
ﬁrmed that tm16 comprises an open reading frame of
399 bp while tm18 has a 393 bp open reading frame. The
predicted amino acid sequence deduced from the cloned
cDNA of tm16 and tm18 is shown in Fig. 2. Tm16 consists
of 133 amino acids and has a predicted mol. wt of
14.79 kDa and an estimated pI of 10.05. Tm18 consists of
131 amino acids and has a predicted mol. wt of
14.65 kDa and a pI of 10.31. Database searches with
Tm16 and Tm18 using BLAST (Altschul et al., 1997) iden-
tiﬁed signiﬁcant BLAST score hits with oncosphere anti-
gens from other taeniid cestodes (shown in Fig. 2).
Predicted secretory signals were identiﬁed in Tm16 and
Tm18 (Fig. 2) using SignalP (Nielsen et al., 1997) and
one putative ﬁbronectin type III domain was also identiﬁed
in each using SMART (Ponting et al., 1999).3.2. Recombinant protein expression
The Tm16 and Tm18 proteins were successfully
expressed in E. coli as fusion proteins with GST, which
facilitated puriﬁcation of the recombinant proteins from
E. coli lysates. The cDNA encoding each recombinant pro-
tein was genetically modiﬁed so that the encoded proteins
lacked the amino acid residues that constituted the pre-
dicted secretory signals. Tm16 and Tm18 were expressed
at moderate levels and were produced as stable, soluble306 713 23 79 116
e2 e3
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Fig. 2. Alignment of the amino acid sequence predicted from cloned mRNA of tm16 (A) and tm18 (B) from T. multiceps with oncosphere antigens from
other Taenia species. Amino acid mismatches are shaded. Boxed amino acids (1–16 for Tm16, A, and 1–18 for Tm18, B) encode putative secretory signals.
Horizontal lines below the alignments deﬁne the polypeptide regions encoded by the three exons (e1–e3). Key amino acid residues deﬁning the ﬁbronectin
type III domain are highlighted with arrows. GenBank Accession Nos. are as follows; To16 (U89944), TSOL16 (AY147841), To18 (U89943), TSOL18
(AF017788) and TSA18 (X98577).
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mobilities in SDS–PAGE that correlated with the size of
the proteins from the predicted amino acid sequences.
The proteins were aﬃnity puriﬁed from the soluble fraction
of E. coli lysate at a purity suitable for application in vac-
cine trials (Fig. 3A and B, lane 3). The truncated Tm16 and
Tm18 proteins were also soluble when expressed as fusion
proteins with MBP (data not shown), allowing the use of
the MBP fusions in ELISA for the measurement of
Tm16- and Tm18-speciﬁc immune responses in vaccinated
sheep.
3.3. Vaccine trial of sheep and experimental challenge with
T. multiceps
Results of the T. multiceps challenge infection in sheep
vaccinated with Tm16 and Tm18 are summarised in Tables
1 and 2. Coenuri ranging in sizes up to 45 mm in diameterwere found (Fig. 4). All control sheep were found to have
T. multiceps at autopsy. There was no statistical diﬀerence
(P = 0.30) between the number of cysts found in the non-
immunised group (one, three, three, ﬁve and twelve para-
sites) and GST-immunised group (two, two, three and
three parasites) and for subsequent analyses, the data from
these two control groups were pooled. Five of the nine con-
trol sheep died as a result of infection with T. multiceps.
Four sheep died during the acute phase of the infection
and one died during the chronic phase prior to the time
at which the remaining sheep were necropsied. One sheep
in the Tm16 group died of causes unrelated to the experi-
ment and no infection data were available for this animal.
None of the 20 remaining immunised sheep died as a result
of the challenge infection (all vaccinated animals versus
controls, P = 0.001). Immunisation with Tm16 induced
statistically signiﬁcant protection against challenge infec-
tion with T. multiceps compared with controls (P = 0.023;
Fig. 3. SDS–PAGE of soluble and insoluble protein extracts of Esche-
richia coli cultures expressing GST fusion proteins and aﬃnity puriﬁed
products. (A) Soluble fraction (lane1), insoluble fraction (lane 2) and
puriﬁed Tm16-GST (lane 3) from E. coli culture expressing Tm16. (B)
Soluble fraction (lane1), insoluble fraction (lane 2) and puriﬁed Tm18-
GST (lane 3) from E. coli culture expressing Tm18. Molecular weight
markers (kDa) are shown on the left of each panel.
Table 1
Numbers of Taenia multiceps coenuri in brains of sheep immunised with
Tm16 and Tm18 compared with control animals
Group Number of coenuri
in individual sheep
P valueb Number of sheep
deaths per group
Controls 1, 2, 2, 3, 3, 3, 3, 5, 12a – 5
Tm16 0, 0, 0, 1, 1, 4 0.023 0
Tm18 0, 0, 0, 0, 1, 3, 7 0.051 0
Tm16 + Tm18 0, 0, 0, 0, 1, 1, 9 0.015 0
a Numbers in bold represent individual animals that died as a result of
the T. multiceps challenge infection.
b The Mann–Whitney U test was used for comparison of the number of
coenuri in vaccinated sheep compared with controls.
Table 2
The location and sizes of Taenia multiceps coenuri in the brains of vaccinated
Number of animals Brain location
Frontal Te
Vaccinated 9 7a (25%)b, 5–10c 13
Controls 9 0 8
Total 18 7 21
a Number of cysts.
b Percentage of total cysts in that treatment group.
c Range in size of cysts (diameter in mm in situ).
Fig. 4. Sheep brain following experimental infection with Taenia multiceps and
for notation of the location of coenuri in the brains of infected sheep is show
1046 C. Gauci et al. / International Journal for Parasitology 38 (2008) 1041–1050Mann–Whitney test, Table 1). Three out of the six sheep
vaccinated with Tm16 harboured no coenuri. Immunisa-
tion of sheep with Tm16 and Tm18 combined, also induced
signiﬁcant protection against infection (P = 0.015), with
four out of the seven animals containing no coenuri.
Although four out of the seven sheep vaccinated with
Tm18 alone were parasite-free, the number of cysts found
in this group was not signiﬁcantly diﬀerent compared with
control animals (P = 0.051). Immunisation with Tm16
and/or Tm18 aﬀected the location of cysts that were found
in vaccinated animals compared with cysts in the control
animals (Table 2). The vaccinated animals had 7/28
(25%) cysts in the parieto-occipital location, whilst there
were 26/34 (76%) in this region in the control animals
(P = 0.027 after adjusting for multiple cysts per animal).
The proportions of cysts in the parieto-occipital location
in each of the nine vaccinated sheep were 2/4, 0/1, 0/1, 1/
1, 2/7, 0/3, 1/1, 1/1 and 0/9, whilst the proportions in the
nine infected control animals were 0/1, 2/2, 3/3, 2/2, 3/3,
1/3, 9/12, 3/5 and 3/3. Due to the death of many control
animals during the acute phase of the infection, compari-
sons were not done for diﬀerences in the sizes of cysts in
vaccinated and control animals.
3.4. Antibody responses
Serological analyses of the antibody responses in sheep
vaccinated with Tm16, Tm18, or both proteins, indicated
that all sheep had seroconverted from being seronegative
prior to immunisation to having readily detectable levelsand control sheep
mporal Parieto-occipital Cerebellar Total
(46%), 3–20 7 (25%), 5–45 1 (4%), 3 28
(24%), 10–25 26 (76%), 9–25 0 34
33 1 62
a coenurus removed from the left parieto-occipital region. The scheme used
n on the right-hand side (after Edwards and Herbert, 1982).
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tein(s) at the time of challenge infection (Fig. 5). All sera
were seronegative for antibodies to MBP (data not shown),
allowing the MBP fusion proteins to be used to assess
Tm16- and Tm18-speciﬁc responses. Control sheep
remained seronegative for speciﬁc antibodies to Tm16 or
Tm18 throughout the experiment (data not shown). All
sheep immunised with Tm16 or Tm18 as well as the control
group immunised with GST developed readily detectable
speciﬁc antibody responses to GST (Fig. 6). Responses
from individual sheep to the three immunisations with
Tm16 or Tm18 varied markedly as did the antibody titre
at the time of challenge, although there was a tendency
for each immunisation to lead to a boost in speciﬁc anti-
body titre (Fig. 5). Antibody responses at the time of chal-
lenge in sheep immunised with Tm16 alone (range 3600–
69,000; mean 27,017 ± 26,610) were greater than those
raised in sheep vaccinated with Tm18 alone (480–24,000;
4851 ± 8539). With the exception of a single animal which
responded to the third immunisation with a prominent rise
in titre, sheep vaccinated with Tm18 induced a relatively
low titre of speciﬁc antibody. This diﬀerence in the level
of response detected to the Tm16 and Tm18 antigens was
also apparent in the animals vaccinated with both proteins
(Fig. 5). The level of speciﬁc antibody response in Tm18
vaccinated animals was also reﬂected in relatively low titres
of antibody being induced to the GST fusion partner in this
group compared with the Tm16 vaccinated group (Fig. 6;
anti-GST titres: Tm16 group 10,530 ± 8096, Tm18 group
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Fig. 7. Relationship between the titre of speciﬁc antibody against Tm16 or
Tm18 antigens detected in individual animals at the time of challenge
infection and the presence (solid symbols) or absence (open circles) of
parasites detected at necropsy. Groups of sheep were vaccinated either
with the Tm16 or Tm18 antigen alone or with a combination of both
Tm16 and Tm18. A and B represent total-speciﬁc IgG to Tm16 and Tm18,
respectively.
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between the titre of speciﬁc antibody to Tm16 or Tm18
and the presence or absence of parasites detected at nec-
ropsy (P = 0.32, n = 13 and P = 0.56, n = 14, respectively;
Mann–Whitney) (Fig. 7). There was no signiﬁcant correla-
tion between the titre to Tm16 or Tm18 and the number of
parasites found in vaccinated animals at necropsy (Spear-
man’s correlation 0.41, P = 0.17, n = 13 for Tm16 and
Spearman’s correlation 0.12, P = 0.69, n = 14 for Tm18).
Three of seven sheep vaccinated with a combined vaccine
containing both Tm16 and Tm18, had anti-Tm16 titres
greater than 10,000 and were found to be free of parasites
after the challenge infection, irrespective of the antibody
titre raised against Tm18. Comparisons of vaccine-speciﬁc
IgG1 and IgG2 antibody isotype titres found no signiﬁcant
association in relation to the presence or absence of para-
sites in individual vaccinated animals (Mann–Whitney U
test; data not shown).4. Discussion
Homologues of the 16k and 18k families of oncosphere
antigens, described previously from various Taenia speciesparasites, were found to be present in T. multiceps and have
been shown here to be capable of being used as vaccines,
inducing a signiﬁcant level of protection against a challenge
infection in sheep with T. multiceps. Of the nine control
sheep which received the challenge infection, ﬁve died as
a result of the presence of parasites in the brain, whereas
none of 20 animals vaccinated with Tm16 and/or Tm18
died following parasite challenge (P = 0.001). In addition,
sheep vaccinated with Tm16, either as a single antigen or
together with Tm18, were found to have signiﬁcantly
reduced numbers of parasites in the brain following the
challenge infection (P = 0.023, P = 0.015, respectively).
There was variability in the location and size of T. multi-
ceps coenuri between individual sheep, with the majority
of cysts being found in either the temporal or parieto-
occipital regions of the brain (Table 2 and Fig. 4). This
was consistent with the pattern of coenuri distribution
observed by Edwards and Herbert (1982) although they
found a slightly higher distribution of coenuri in the frontal
and cerebellar regions of the brain compared with this
study. Vaccination appeared to have an eﬀect on the site
in which cysts were located compared with the control ani-
mals, with a smaller proportion of cysts detected in the
parieto-occipital region of the brain in vaccinated sheep.
The principal or only immune mechanism associated
with protective immune responses against taeniid cestode
parasites in their intermediate hosts is antibody and com-
plement mediated lysis of the early developing oncosphere
(Rickard and Williams, 1982; Lightowlers et al., 2003).
Speciﬁc antibodies in the sera of animals vaccinated with
oncosphere antigens can be shown to be lethal to the early
developing oncosphere in a number of Taenia species
(Kyngdon et al., 2006) but this has not been determined
for T. multiceps. For these reasons, we investigated whether
the protective responses induced by Tm16 or Tm18 are
associated with the induction of speciﬁc IgG antibodies.
The Tm16 and Tm18 recombinant antigens were expressed
as MBP fusion proteins allowing the level of Tm16- and
Tm18-speciﬁc antibodies to be evaluated in the sera of
the sheep which were vaccinated with GST fusion proteins.
However, no clear relationship was apparent between the
level of speciﬁc antibody to Tm16 or Tm18 and the pres-
ence or absence of parasites found at necropsy. Also, no
correlation was evident between the speciﬁc antibody titre
and the number of parasites found in vaccinated animals
at necropsy (P = 0.051; Fig. 7). Nevertheless, inspection
of the speciﬁc antibody titres in the group vaccinated with
both Tm16 and Tm18 suggested a possible protective syn-
ergy between these two antigens (Fig. 7). Three animals
with the highest anti-Tm16 titres were all found to be free
of parasites at necropsy, irrespective of the level of their
speciﬁc titres to Tm18. Synergic, protective immune
responses have been described previously between mem-
bers of the 18k and 45W families of oncosphere antigens
from T. saginata (Lightowlers et al., 1996b).
The tm16 and tm18 genes show conserved DNA
sequence and structural features that are also present in
C. Gauci et al. / International Journal for Parasitology 38 (2008) 1041–1050 1049related genes from the other taeniid species (Waterkeyn
et al., 1995; Gauci et al., 1998; Chow et al., 2001; Gauci
and Lightowlers, 2003). After cloning and DNA sequenc-
ing of the mRNA encoded by the tm16 and tm18 genes
the structure of the genes was conﬁrmed by DNA sequence
alignment. The intron/exon structures of tm16 and tm18
are similar to the homologous genes in T. ovis and T. soli-
um (Gauci and Lightowlers, 2003). Exons 1 and 2 of tm16
and tm18 encode modular proteins that contain a predicted
secretory signal and a ﬁbronectin type III domain, respec-
tively. This is supported by amino acid sequence align-
ments (Fig. 2) which show that the T. multiceps antigens
share amino acid sequences common to T. ovis and T. soli-
um and that amino acids identiﬁed as critical to the ﬁbro-
nectin type III domain (Lightowlers et al., 2000) are also
conserved in Tm16 and Tm18. The conformation of ces-
tode oncosphere antigens has been shown to be important
for maintenance of host protective epitopes within the anti-
gens (Woollard et al., 2001) and it is possible that the con-
formation of Tm16 and Tm18, provided by the ﬁbronectin
type III domain, may also be important for host
protection.
The Tm16 and Tm18 genes and their associated mRNAs
were cloned from T. multiceps specimens originating from
diﬀerent geographical regions (Wales, UK and Turkey,
respectively), however no DNA sequence diﬀerences were
observed in their protein-encoding regions. The genes were
also subsequently PCR-ampliﬁed and sequenced from
Turkish parasite material recovered from sheep used in this
study. No DNA sequence diﬀerences were observed for
Tm16 and Tm18 in the diﬀerent isolates, despite diﬀerences
being identiﬁed in their cytochrome c-oxidase genes (data
not shown). This suggests that isolates of T. multiceps from
diﬀerent geographical locations may show limited or no
antigenic variability, in relation to Tm16 and Tm18,
despite the known existence of substantial genetic variation
between diﬀerent isolates of this parasite species (Varcasia
et al., 2006).
The levels of protection that were achieved here against
infection with T. multiceps were lower than the high levels
of protection that have been demonstrated with other tae-
niid cestode vaccines (Johnson et al., 1989; Harrison et al.,
1996; Lightowlers et al., 1996a,b, 1999; Flisser et al., 2004;
Gonzalez et al., 2005). There are several reasons why this
may have been the case. The level of antibody response
which was achieved here against the Tm16 and, especially,
the Tm18 antigens was relatively low compared with the
level of response that has been achieved in sheep against
other recombinant taeniid cestode antigens (Rothel et al.,
1996; Woollard et al., 1998). The Tm18 antigen does not
seem to be a poor immunogen per se because sheep subse-
quently immunised with this antigen in Australia, using an
identical vaccination schedule, were found to have anti-
body titres substantially higher than those found in sera
from the sheep trial in Turkey (data not shown). These dif-
ferences may be associated with other factors such as the
diﬀerent sheep breeds used. Therefore, potential exists forachieving a higher level of protection by optimising the
dose, schedule and formulation of the antigens. Another
reason for the relative low level of protection achieved
against T. multiceps may relate to the diﬀerent biology of
T. multiceps compared with the other Taenia species for
which vaccines have been developed, i.e. T. ovis, T. saginat-
a and T. solium. The metacestode of T. multiceps encysts in
the brain, while the other species infect skeletal muscle. The
brain is an immunologically privileged site and it may be
that there is little time for the animal’s immune response
to kill the invading T. multiceps oncosphere compared with
the muscle-encysting Taenia species. If a lethal impact has
not been inﬂicted on the T. multiceps oncosphere prior to
its penetration of the brain, it may thereafter be protected
from serum antibodies and complement because of its loca-
tion in the brain.
We believe this study is the ﬁrst description of vaccine-
related investigations on T. multiceps. It provides a basis
upon which a practical vaccine against T. multiceps could
be developed for the sheep intermediate host and may also
allow the development of a combined vaccine together with
the E. granulosus vaccine antigen EG95 (Lightowlers et al.,
1996a). Incorporation of the hydatid vaccine within an eco-
nomically valuable T. multiceps vaccine could provide the
necessary economic incentive needed to achieve uptake of
hydatid vaccination and control of this important zoonotic
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